Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
A blockbuster oncology drug showed great promise in new indications, but the pharmaceutical company marketing the drug did not have the capacity to supply the 125,000 vials per month that would be needed to support its new clinical trials.
Download this case study to learn how: